HB1099 — reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

HB1099 — reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance. · Informed CitizenryHouse Bill 1099 seeks to modify how psilocybin, a compound found in certain natural sources and currently classified as a Schedule IV controlled substance, can be formulated into a drug product app…Open in Informed Citizenry